Therapeutics: Multiple kinase targets; an undisclosed target


INDICATION: Cancer; breast cancer; lung cancer

Mouse studies suggest the mitochondrial inhibitor ME-344 and/or the multikinase inhibitor Vargatef nintedanib could help treat kinase inhibitor-resistant cancers. In a mouse model of Stivarga regorafenib-resistant metastatic breast

Read the full 332 word article

How to gain access

Continue reading with a
two-week free trial.